The antibody reacts mainly with high molecular weight (190-220kDa) form of leukocyte common antigen. Labels all B lymphocytes and 50% of bone marrow cells and 2% of thymocytes. The antibody is directed against CD8+ve T, NK and 75% of CD4+ve cells. Same distribution as OX-32: antibodies do not compete.
| Institute |
|---|
| Medical Research Council; University of Oxford |
| Cat. #: | 156568 |
|---|---|
| Unit size: | 100 ug |
| Application: | FACS ; IHC |
| Target: | CD45RC |
| Reactivity: | Rat |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | The antibody reacts mainly with high molecular weight (190-220kDa) form of leukocyte common antigen. Labels all B lymphocytes and 50% of bone marrow cells and 2% of thymocytes. The antibody is directed against CD8+ve T, NK and 75% of CD4+ve cells. Same distribution as OX-32: antibodies do not compete. |
|---|---|
| Conjugation: | Unconjugated |
| Immunogen: | PHA activated rat lymph node cells |
| Myeloma used: | NS1 |
| Target background: | The antibody reacts mainly with high molecular weight (190-220kDa) form of leukocyte common antigen. Labels all B lymphocytes and 50% of bone marrow cells and 2% of thymocytes. The antibody is directed against CD8+ve T, NK and 75% of CD4+ve cells. Same distribution as OX-32: antibodies do not compete. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Spickett et al. 1983. J Exp Med. 158(3):795-810. PMID: 6224884. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.